Literature DB >> 19692462

Race between retroviral spread and CD4+ T-cell response determines the outcome of acute Friend virus infection.

Rebecca Pike1, Andrew Filby, Mickaël J-Y Ploquin, Urszula Eksmond, Rute Marques, Inês Antunes, Kim Hasenkrug, George Kassiotis.   

Abstract

Retroviruses can establish persistent infection despite induction of a multipartite antiviral immune response. Whether collective failure of all parts of the immune response or selective deficiency in one crucial part underlies the inability of the host to clear retroviral infections is currently uncertain. We examine here the contribution of virus-specific CD4(+) T cells in resistance against Friend virus (FV) infection in the murine host. We show that the magnitude and duration of the FV-specific CD4(+) T-cell response is directly proportional to resistance against acute FV infection and subsequent disease. Notably, significant protection against FV-induced disease is afforded by FV-specific CD4(+) T cells in the absence of a virus-specific CD8(+) T-cell or B-cell response. Enhanced spread of FV infection in hosts with increased genetic susceptibility or coinfection with Lactate dehydrogenase-elevating virus (LDV) causes a proportional increase in the number of FV-specific CD4(+) T cells required to control FV-induced disease. Furthermore, ultimate failure of FV/LDV coinfected hosts to control FV-induced disease is accompanied by accelerated contraction of the FV-specific CD4(+) T-cell response. Conversely, an increased frequency or continuous supply of FV-specific CD4(+) T cells is both necessary and sufficient to effectively contain acute infection and prevent disease, even in the presence of coinfection. Thus, these results suggest that FV-specific CD4(+) T cells provide significant direct protection against acute FV infection, the extent of which critically depends on the ratio of FV-infected cells to FV-specific CD4(+) T cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19692462      PMCID: PMC2772778          DOI: 10.1128/JVI.01225-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

Review 1.  Friend erythroleukemia revisited.

Authors:  P A Ney; A D D'Andrea
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Use of a transient assay for studying the genetic determinants of Fv1 restriction.

Authors:  M Bock; K N Bishop; G Towers; J P Stoye
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  An optimized CD4 T-cell response can control productive and latent gammaherpesvirus infection.

Authors:  Rebecca L Sparks-Thissen; Douglas C Braaten; Scott Kreher; Samuel H Speck; Herbert W Virgin
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

4.  Role of natural killer cells in resistance against friend retrovirus-induced leukemia.

Authors:  N Iwanami; A Niwa; Y Yasutomi; N Tabata; M Miyazawa
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  HIV preferentially infects HIV-specific CD4+ T cells.

Authors:  Daniel C Douek; Jason M Brenchley; Michael R Betts; David R Ambrozak; Brenna J Hill; Yukari Okamoto; Joseph P Casazza; Janaki Kuruppu; Kevin Kunstman; Steven Wolinsky; Zvi Grossman; Mark Dybul; Annette Oxenius; David A Price; Mark Connors; Richard A Koup
Journal:  Nature       Date:  2002-05-02       Impact factor: 49.962

6.  CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells.

Authors:  Z Qin; T Blankenstein
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

7.  CD4(+) T cells and gamma interferon in the long-term control of persistent friend retrovirus infection.

Authors:  M Iwashiro; K Peterson; R J Messer; I M Stromnes; K J Hasenkrug
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

8.  Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells.

Authors:  Casper Paludan; Kara Bickham; Sarah Nikiforow; Ming L Tsang; Kiera Goodman; Willem A Hanekom; Jean-Francois Fonteneau; Stefan Stevanović; Christian Münz
Journal:  J Immunol       Date:  2002-08-01       Impact factor: 5.422

9.  Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection.

Authors:  Mario L Santiago; Mauricio Montano; Robert Benitez; Ronald J Messer; Wes Yonemoto; Bruce Chesebro; Kim J Hasenkrug; Warner C Greene
Journal:  Science       Date:  2008-09-05       Impact factor: 47.728

10.  Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas.

Authors:  Koen Schepers; Mireille Toebes; Gitte Sotthewes; Florry A Vyth-Dreese; Trees A M Dellemijn; Cornelis J M Melief; Ferry Ossendorp; Ton N M Schumacher
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

View more
  26 in total

1.  Elimination of friend retrovirus in the absence of CD8+ T cells.

Authors:  Sachiyo Tsuji-Kawahara; Masaaki Miyazawa
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

2.  Host resistance influences patterns of experimental viral adaptation and virulence evolution.

Authors:  Jason L Kubinak; Wayne K Potts
Journal:  Virulence       Date:  2013-04-17       Impact factor: 5.882

3.  HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome.

Authors:  Damien Z Soghoian; Heiko Jessen; Michael Flanders; Kailan Sierra-Davidson; Sam Cutler; Thomas Pertel; Srinika Ranasinghe; Madelene Lindqvist; Isaiah Davis; Kimberly Lane; Jenna Rychert; Eric S Rosenberg; Alicja Piechocka-Trocha; Abraham L Brass; Jason M Brenchley; Bruce D Walker; Hendrik Streeck
Journal:  Sci Transl Med       Date:  2012-02-29       Impact factor: 17.956

4.  Medroxyprogesterone acetate impairs human dendritic cell activation and function.

Authors:  N E Quispe Calla; M G Ghonime; T L Cherpes; R D Vicetti Miguel
Journal:  Hum Reprod       Date:  2015-03-03       Impact factor: 6.918

5.  Immunology and the elusive AIDS vaccine.

Authors:  Herbert W Virgin; Bruce D Walker
Journal:  Nature       Date:  2010-03-11       Impact factor: 49.962

6.  B cells and TCR avidity determine distinct functions of CD4+ T cells in retroviral infection.

Authors:  Mickaël J-Y Ploquin; Urszula Eksmond; George Kassiotis
Journal:  J Immunol       Date:  2011-08-12       Impact factor: 5.422

7.  The anti-caspase inhibitor Q-VD-OPH prevents AIDS disease progression in SIV-infected rhesus macaques.

Authors:  Mireille Laforge; Ricardo Silvestre; Vasco Rodrigues; Julie Garibal; Laure Campillo-Gimenez; Shahul Mouhamad; Valérie Monceaux; Marie-Christine Cumont; Henintsoa Rabezanahary; Alain Pruvost; Anabela Cordeiro-da-Silva; Bruno Hurtrel; Guido Silvestri; Anna Senik; Jérôme Estaquier
Journal:  J Clin Invest       Date:  2018-03-19       Impact factor: 14.808

Review 8.  Tetherin/BST-2: Restriction Factor or Immunomodulator?

Authors:  Sam X Li; Bradley S Barrett; Kejun Guo; Mario L Santiago
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

9.  HIV vaccines: can CD4+ T cells be of help?

Authors:  Eva Van Braeckel; Geert Leroux-Roels
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

10.  A DNA vaccine encoding multiple HIV CD4 epitopes elicits vigorous polyfunctional, long-lived CD4+ and CD8+ T cell responses.

Authors:  Daniela Santoro Rosa; Susan Pereira Ribeiro; Rafael Ribeiro Almeida; Eliane Conti Mairena; Edilberto Postól; Jorge Kalil; Edecio Cunha-Neto
Journal:  PLoS One       Date:  2011-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.